非病毒DNA递送平台Tethosome归属礼来公司

发布时间：2026-05-22来源：D-Pharm

Engage Biologics Inc., a preclinical biotechnology company pioneering non-viral

Engage Biologics Inc.，一家处于临床前阶段的生物技术公司，致力于非病毒性的开创性研究

DNA

delivery, announced that it has been acquired by Eli Lilly and Company.

交付，宣布已被礼来公司收购。

Engage is developing the Tethosome platform, a novel non-viral DNA delivery system designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosability. The platform combines engineered DNA payloads with lipid nanoparticle delivery and an mRNA-encoded proprietary Tethosome technology designed to enhance localization and increase expression.

Engage公司正在开发Tethosome平台，这是一种新型的非病毒DNA递送系统，旨在克服DNA递送中的关键限制，包括效力、耐受性和可重复给药性。该平台将工程化DNA载荷与脂质纳米颗粒递送技术相结合，并采用mRNA编码的专有Tethosome技术，旨在增强定位并提高表达水平。

Engage’s DNA payloads are further engineered to improve tolerability while retaining key advantages of DNA-based therapies, including durability and programmability..

Engage的DNA有效载荷进一步经过工程改造，以提高耐受性，同时保留了基于DNA的疗法的关键优势，包括持久性和可编程性。

“With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines. This is a testament to what a nimble, passionate team can achieve with the tools of synthetic biology,” said Will Olsen, Co-Founder and CEO of Engage.

“凭借精简的团队和适度的种子资金，我为Engage在新型基因药物领域取得的快速进展感到无比自豪。这充分证明了灵活且充满热情的团队通过合成生物学工具所能实现的成就，”Engage联合创始人兼首席执行官威尔·奥尔森表示。

“We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine. We believe that the combination of Engage’s platform with Lilly’s significant capabilities will meaningfully accelerate development of new genetic therapies.”.

“我们很高兴能与礼来公司开启下一个篇章，礼来展现了无与伦比的速度和前瞻性的基因药物研发方法。我们相信，Engage平台与礼来强大能力的结合将显著加速新型基因疗法的开发。”

Under the terms of the agreement, Lilly acquired Engage for up to $202 million in cash, including an upfront payment and subsequent payments upon achievement of specified development milestones.

根据协议条款，礼来公司以高达2.02亿美元的现金收购了Engage，其中包括首付款以及在达成特定开发里程碑后的后续付款。

https://www.bionity.com/en/news/1188750/non-viral-dna-delivery-platform-tethosome-goes-to-eli-lilly.html

New DNA synthesis technique promises rapid, high-fidelity DNA printing

新型DNA合成技术有望实现快速、高保真的DNA打印

Read news

读新闻